Cargando…

Survival Following Segmentectomy or Lobectomy in Patients With Stage IB Non-small-cell Lung Cancer

Background: Lobectomy with mediastinal lymph node dissection has always been recognized as the standardized treatment for early-stage non-small-cell lung cancer. However, the feasibility of segmentectomy performed in stage IB non-small-cell lung cancer (NSCLC) patients remains controversial. The pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Bo, Zhang, Lin, Fan, Tao, Liu, Bohao, Jiang, Wenyang, Hu, Hao, Geng, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243118/
https://www.ncbi.nlm.nih.gov/pubmed/32500023
http://dx.doi.org/10.3389/fonc.2020.00661
_version_ 1783537370215219200
author Hao, Bo
Zhang, Lin
Fan, Tao
Liu, Bohao
Jiang, Wenyang
Hu, Hao
Geng, Qing
author_facet Hao, Bo
Zhang, Lin
Fan, Tao
Liu, Bohao
Jiang, Wenyang
Hu, Hao
Geng, Qing
author_sort Hao, Bo
collection PubMed
description Background: Lobectomy with mediastinal lymph node dissection has always been recognized as the standardized treatment for early-stage non-small-cell lung cancer. However, the feasibility of segmentectomy performed in stage IB non-small-cell lung cancer (NSCLC) patients remains controversial. The present study aims to investigate whether the outcome of stage IB NSCLC patients undergoing segmentectomy was comparable to those who underwent lobectomy. Method: We retrospectively collected data of 11,010 patients with primary stage IB non-small-cell lung cancer from the Surveillance, Epidemiology, and End Results database. Overall survival (OS) and lung cancer-specific survival (LCSS) were assessed among patients who were performed lobectomy or segmentectomy. To further assess the impact of the surgical procedures on patients with different tumor sizes, subgroups stratified by tumor size were analyzed. Results: A total of 11,010 patients who were pathologically confirmed to be stage IB were included, of whom 10,453 received lobectomy and 557 received segmentectomy. Both univariate and multivariate Cox regression analyses showed that the patients receiving lobectomy had better OS [hazards ratio (HR) = 1.197, 95% confidence interval (CI) (1.066, 1.343), P < 0.001] than those receiving segmentectomy. However, multivariate analysis showed that there was no significant difference in LCSS between lobectomy and segmentectomy [HR = 1.172, 95% CI (0.963, 1.427), P = 0.114]. Meanwhile, subgroup analyses showed that lobectomy rather than segmentectomy was associated with better OS [HR = 1.278, 95% CI (1.075, 1.520) P = 0.006] and LCSS [HR = 1.118, 95% CI (1.005, 1.280), P = 0.047] for patients with a tumor size (TS) of ≤ 40 and >30 mm, while for patients with a TS of ≤ 30 mm, lobectomy yielded similar OS [TS ≤ 20 mm: HR = 1.068, 95% CI (0.853, 1.336), P = 0.566; TS > 20 mm and ≤ 30 mm: HR = 1.195, 95% CI (0.961, 1.487), P = 0.109] and LCSS [TS ≤ 20 mm: HR = 1.029, 95% CI: (0.682, 1.552), P = 0.893; TS > 20 and ≤ 30 mm: HR = 1.144, 95% CI (0.795, 1.645), P = 0.469] to that of segmentectomy. Conclusion: Segmentectomy achieved equivalent OS and LCSS in stage IB NSCLC patients with TS ≤ 30 mm compared with lobectomy. Lobectomy showed better OS and LCSS than segmentectomy for patients with a TS of >30 and ≤ 40 mm. Segmentectomy may be acceptable in patients with an older age and a smaller TS.
format Online
Article
Text
id pubmed-7243118
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72431182020-06-03 Survival Following Segmentectomy or Lobectomy in Patients With Stage IB Non-small-cell Lung Cancer Hao, Bo Zhang, Lin Fan, Tao Liu, Bohao Jiang, Wenyang Hu, Hao Geng, Qing Front Oncol Oncology Background: Lobectomy with mediastinal lymph node dissection has always been recognized as the standardized treatment for early-stage non-small-cell lung cancer. However, the feasibility of segmentectomy performed in stage IB non-small-cell lung cancer (NSCLC) patients remains controversial. The present study aims to investigate whether the outcome of stage IB NSCLC patients undergoing segmentectomy was comparable to those who underwent lobectomy. Method: We retrospectively collected data of 11,010 patients with primary stage IB non-small-cell lung cancer from the Surveillance, Epidemiology, and End Results database. Overall survival (OS) and lung cancer-specific survival (LCSS) were assessed among patients who were performed lobectomy or segmentectomy. To further assess the impact of the surgical procedures on patients with different tumor sizes, subgroups stratified by tumor size were analyzed. Results: A total of 11,010 patients who were pathologically confirmed to be stage IB were included, of whom 10,453 received lobectomy and 557 received segmentectomy. Both univariate and multivariate Cox regression analyses showed that the patients receiving lobectomy had better OS [hazards ratio (HR) = 1.197, 95% confidence interval (CI) (1.066, 1.343), P < 0.001] than those receiving segmentectomy. However, multivariate analysis showed that there was no significant difference in LCSS between lobectomy and segmentectomy [HR = 1.172, 95% CI (0.963, 1.427), P = 0.114]. Meanwhile, subgroup analyses showed that lobectomy rather than segmentectomy was associated with better OS [HR = 1.278, 95% CI (1.075, 1.520) P = 0.006] and LCSS [HR = 1.118, 95% CI (1.005, 1.280), P = 0.047] for patients with a tumor size (TS) of ≤ 40 and >30 mm, while for patients with a TS of ≤ 30 mm, lobectomy yielded similar OS [TS ≤ 20 mm: HR = 1.068, 95% CI (0.853, 1.336), P = 0.566; TS > 20 mm and ≤ 30 mm: HR = 1.195, 95% CI (0.961, 1.487), P = 0.109] and LCSS [TS ≤ 20 mm: HR = 1.029, 95% CI: (0.682, 1.552), P = 0.893; TS > 20 and ≤ 30 mm: HR = 1.144, 95% CI (0.795, 1.645), P = 0.469] to that of segmentectomy. Conclusion: Segmentectomy achieved equivalent OS and LCSS in stage IB NSCLC patients with TS ≤ 30 mm compared with lobectomy. Lobectomy showed better OS and LCSS than segmentectomy for patients with a TS of >30 and ≤ 40 mm. Segmentectomy may be acceptable in patients with an older age and a smaller TS. Frontiers Media S.A. 2020-05-15 /pmc/articles/PMC7243118/ /pubmed/32500023 http://dx.doi.org/10.3389/fonc.2020.00661 Text en Copyright © 2020 Hao, Zhang, Fan, Liu, Jiang, Hu and Geng. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Hao, Bo
Zhang, Lin
Fan, Tao
Liu, Bohao
Jiang, Wenyang
Hu, Hao
Geng, Qing
Survival Following Segmentectomy or Lobectomy in Patients With Stage IB Non-small-cell Lung Cancer
title Survival Following Segmentectomy or Lobectomy in Patients With Stage IB Non-small-cell Lung Cancer
title_full Survival Following Segmentectomy or Lobectomy in Patients With Stage IB Non-small-cell Lung Cancer
title_fullStr Survival Following Segmentectomy or Lobectomy in Patients With Stage IB Non-small-cell Lung Cancer
title_full_unstemmed Survival Following Segmentectomy or Lobectomy in Patients With Stage IB Non-small-cell Lung Cancer
title_short Survival Following Segmentectomy or Lobectomy in Patients With Stage IB Non-small-cell Lung Cancer
title_sort survival following segmentectomy or lobectomy in patients with stage ib non-small-cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243118/
https://www.ncbi.nlm.nih.gov/pubmed/32500023
http://dx.doi.org/10.3389/fonc.2020.00661
work_keys_str_mv AT haobo survivalfollowingsegmentectomyorlobectomyinpatientswithstageibnonsmallcelllungcancer
AT zhanglin survivalfollowingsegmentectomyorlobectomyinpatientswithstageibnonsmallcelllungcancer
AT fantao survivalfollowingsegmentectomyorlobectomyinpatientswithstageibnonsmallcelllungcancer
AT liubohao survivalfollowingsegmentectomyorlobectomyinpatientswithstageibnonsmallcelllungcancer
AT jiangwenyang survivalfollowingsegmentectomyorlobectomyinpatientswithstageibnonsmallcelllungcancer
AT huhao survivalfollowingsegmentectomyorlobectomyinpatientswithstageibnonsmallcelllungcancer
AT gengqing survivalfollowingsegmentectomyorlobectomyinpatientswithstageibnonsmallcelllungcancer